TIDMAGL
RNS Number : 2731B
Angle PLC
03 April 2017
For immediate release 3 April 2017
ANGLE plc ("the Company")
PARSORTIX ENABLES GENE EXPRESSION ANALYSIS IN HEAD AND NECK
CANCER
Customer presents clinically relevant results at AACR 2017 with
Parsortix where alternative approaches have failed
University of Athens, Attikon University Hospital, Greece first
to demonstrate use of the Parsortix system in head and neck
cancer
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is delighted to announce that the University of Athens and Attikon
University Hospital, Greece are today presenting highly encouraging
results from their work with ANGLE's Parsortix system in head and
neck squamous cell carcinomas at the American Association for
Cancer Research conference (AACR) 2017, in Washington DC.
The results show that in a study of 40 cancer patients, the
Parsortix system demonstrated higher sensitivity and greater purity
in harvesting CTCs for analysis than leading alternative
approaches. Information regarding the expression of key genes
(including PD-L1 and CK-19) could be determined from simple blood
samples taken from each patient. In parallel, identical samples
from each patient were assessed using antibody-based
(EpCAM-dependent) approaches. These approaches failed to detect
PD-L1 or CK-19 in any of the 40 samples.
The University of Athens work suggest that, for the first time,
it might be possible to assess gene expression of head and neck
cancers using a Parsortix non-invasive liquid biopsy. Gene
expression of biomarkers such as PD-L1 provides key information
regarding likely patient response to immunotherapies and has the
potential to be of significant clinical importance for the therapy
selection and follow-up of patients.
Head and neck cancer is the sixth most common cancer worldwide
with over 600,000 new patients diagnosed annually resulting in more
than 350,000 deaths every year. More than 90% of head and neck
cancers are squamous cell carcinomas (HNSCC) which account for
5-10% of all new cancer cases in Europe and North America.
Head and neck cancer represents a new market opportunity for
Parsortix as other liquid biopsy approaches have been unsuccessful
in this indication: gene expression analysis cannot be achieved
with antibody-based CTC systems due to low expression of EpCAM and
cannot be achieved using alternative ctDNA approaches as it is
based on RNA.
Prof Evi Lianidou, Head of the Molecular Diagnostics Laboratory
focused on Liquid Biopsy, University of Athens, commented:
"The low EpCAM expression in head and neck cancer has previously
prevented us from liquid biopsy analysis. The Parsortix system's
epitope independence, high sensitivity and purity now makes this
possible. Our results show excellent RNA quality and the potential
to analyse a simple blood test to provide key gene expression
information."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The advantages of the Parsortix system, in head and neck
cancer, over the existing antibody-based approaches increases the
market opportunity available to ANGLE. The University of Athens is
a leader in CTC research and the successful completion of this work
by a customer validates a key element of our roll-out strategy of
using research-use sales to drive the development of clinical
applications for the Parsortix system."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser),
Steve Cox
Russell Kerr (Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXLAEFXXEFF
(END) Dow Jones Newswires
April 03, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024